The nonprofit Multidisciplinary Association for Psychedelic Studies’ (MAPS) has announced its clinical research programme has had a successful confirmatory Phase 3 trial of MDMA-assisted therapy for...
Tryp Therapeutics and MGH will fund and conduct a Phase 2a clinical trial investigating the effects of psilocybin-assisted psychotherapy in the treatment of patients suffering from...
A new study, led by University of California – Riverside (UCR) doctoral ethnomusicology student Owain J.
The therapeutic benefits of many psychedelics have been clearly demonstrated through clinical trials, where the use of psilocybin-, ketamine-, and MDMA-assisted psychotherapy showed striking long-term improvements...
Researchers at Johns Hopkins Medicine have found that just a single psychedelic experience may increase a range of beliefs about consciousness, meaning and purpose.
Germany’s Federal Ministry of Education and Research (BMBF) has provided a grant of €2.6m for a study exploring the efficacy of psilocybin as a treatment for...
Data from Diamond Therapeutics’ trial is the first to identify a safe, active and non-psychedelic dosage of psilocybin, which the company says could open the possibility...
COMPASS Pathways has presented new, positive data demonstrating the potential of COMP360 psilocybin therapy in depression at the Annual Meeting of the American College of Neuropsychopharmacology...
An increasing amount of research is investigating the efficacy of psychedelic mushrooms for the treatment of a number of health conditions, however, knowledge about how psychedelic...
KGK Science and Nova Mentis Life Science will carry out a Phase 2a clinical trial testing the efficacy of psilocybin microdosing on Fragile X Syndrome.